Free tool
FAERS Monitor: Cleocin T
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050615 or its brand name (Cleocin T, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.
Reports
3,969
Serious
2,541
64% of reports
Hospitalization
1,194
Death reported
292
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective386
- rash285
- off label use258
- drug hypersensitivity240
- nausea227
- diarrhoea226
- fatigue211
- pruritus186
- pain178
- condition aggravated151
- headache136
- dyspnoea135
- pyrexia122
- vomiting117
- malaise111
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 63 |
| 2006 | 62 |
| 2007 | 15 |
| 2008 | 30 |
| 2009 | 48 |
| 2010 | 93 |
| 2011 | 83 |
| 2012 | 115 |
| 2013 | 109 |
| 2014 | 117 |
| 2015 | 147 |
| 2016 | 277 |
| 2017 | 200 |
| 2018 | 253 |
| 2019 | 298 |
| 2020 | 227 |
| 2021 | 217 |
| 2022 | 312 |
| 2023 | 325 |
| 2024 | 317 |
| 2025 | 345 |
| 2026 | 293 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 240 | 6.6 | 5.8 | 1,139 |
| rashSignal | 285 | 3.5 | 3.1 | 508 |
| condition aggravatedSignal | 151 | 2.6 | 2.3 | 153 |
| pruritusSignal | 186 | 2.6 | 2.2 | 179 |
| pyrexia | 122 | 1.9 | 1.6 | 49 |
| diarrhoea | 226 | 1.9 | 1.6 | 91 |
| off label use | 258 | 1.6 | 1.4 | 54 |
| drug ineffective | 386 | 1.6 | 1.4 | 80 |
| pain | 178 | 1.5 | 1.3 | 34 |
| nausea | 227 | 1.5 | 1.3 | 41 |
| fatigue | 211 | 1.4 | 1.3 | 29 |
| malaise | 111 | 1.3 | 1.1 | 9 |
| vomiting | 117 | 1.3 | 1.1 | 9 |
| dyspnoea | 135 | 1.3 | 1.1 | 7 |
| headache | 136 | 1.1 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.